| Name | Title | Contact Details |
|---|---|---|
Steven Yoo |
Chief Financial Officer | Profile |
Morris Denton |
Chief Executive Officer | Profile |
ThermoGenesis Holdings, Inc. is an industry leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We offer a full suite of solutions for automated clinical biobanking, point-of-care applications, and large scale cell processing and manufacturing for the emerging CAR-T immunotherapy market.
Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.